2 型糖尿病血管并发症的风险因素回顾及临床预测模型的应用

李 贞林, 杨 卡明, 劳 琬文, 毕长 龙*
中山大学附属第八医院（深圳福田）内分泌科

摘要

2 型糖尿病目前已经成为一种严重威胁人类健康的疾病，根据国际糖尿病协会预测，到 2015 年，全世界糖尿病患
者数量将达到 4.15 亿，而到 2040 年将突破 6.4 亿。1、2 型糖尿病是一种很普遍的疾病，但是它与高致残率和高致死率密切
相关。其中，大血管病变包括心血管疾病、脑卒中及周围血管病变等，而小血管病变则包括神经病变、肾脏病及视网膜病变等。
目前，预测性建模已逐步发展为一种有效的辅助治疗手段，特别是对早期发现的病人，利用该方法可以极大地提升疾病的
诊断效果，节省费用。本文通过对当前已被认可的糖尿病血管并发症危险因子进行了回顾性总结，并对当前研究中的这些
预测模型的优缺点进行了比较。

关键词

2 型糖尿病；糖尿病并发症；风险因素；预测模型

参考

[1] FEDERATION. I D. IDF Atlas. 7th edition. [Z]. 2015.

[2] CHINESE DIABETES S. Guideline for the prevention

and treatment of type 2 diabetes mellitus in China(2020 edition) [J].

Chinese Journal of Endocrinology and Metabolism, 2021, 37(4):

311-98.

[3] Global, regional, and national age-sex specific all_xfffe_cause and cause-specific mortality for 240 causes of death, 1990-

2013: a systematic analysis for the Global Burden of Disease Study

2013 [J]. Lancet, 2015, 385(9963): 117-71.

[4] FU J, PRASAD H C. Changing epidemiology of

metabolic syndrome and type 2 diabetes in Chinese youth [J]. Curr

Diab Rep, 2014, 14(1): 447.

[5] S C H E L L E N B E R G E S , D R Y D E N D M ,

VANDERMEER B, et al. Lifestyle interventions for patients with

and at risk for type 2 diabetes: a systematic review and meta_xfffe_analysis [J]. Ann Intern Med, 2013, 159(8): 543-51.

[6] BERGHEANU S C, BODDE M C, JUKEMA J W.

Pathophysiology and treatment of atherosclerosis : Current view

and future perspective on lipoprotein modification treatment [J].

Neth Heart J, 2017, 25(4): 231-42.

[7] ORMAZABAL V, NAIR S, ELFEKY O, et al.

Association between insulin resistance and the development of

cardiovascular disease [J]. Cardiovasc Diabetol, 2018, 17(1): 122.

[8] MOHAMMEDI K, WOODWARD M, HIRAKAWA Y,

et al. Presentations of major peripheral arterial disease and risk of

major outcomes in patients with type 2 diabetes: results from the

ADVANCE-ON study [J]. Cardiovasc Diabetol, 2016, 15(1): 129.

[9] SACKS D, BAXTER B, CAMPBELL B C V, et al.

Multisociety Consensus Quality Improvement Revised Consensus

Statement for Endovascular Therapy of Acute Ischemic Stroke [J].

Int J Stroke, 2018, 13(6): 612-32.

[10]MOHAMMEDI K, WOODWARD M, ZOUNGAS S,

et al. Absence of Peripheral Pulses and Risk of Major Vascular

Outcomes in Patients With Type 2 Diabetes [J]. Diabetes Care,

2016, 39(12): 2270-7.

[11]CRIQUI M H, ABOYANS V. Epidemiology of peripheral

artery disease [J]. Circ Res, 2015, 116(9): 1509-26.

[12]CHENG B, JIANG Y, FU X, et al. Epidemiological

characteristics and clinical analyses of chronic cutaneous wounds

of inpatients in China: Prevention and control [J]. Wound Repair

Regen, 2020, 28(5): 623-30.

[13] VAN NETTEN J J, BUS S A, APELQVIST J, et al.

Definitions and criteria for diabetic foot disease [J]. Diabetes

Metab Res Rev, 2020, 36 Suppl 1: e3268.

[14] Rutherford's Vascular Surgery and Endovascular

Therapy, E-Book, 9th Edition 03-04-2018:

[15] BOUWMEESTER W, ZUITHOFF N P, MALLETT S,

et al. Reporting and methods in clinical prediction research: a

systematic review [J]. PLoS Med, 2012, 9(5): 1-12.

[16] RASMUSSEN A, ALMDAL T, ANKER NIELSEN A,

et al. Decreasing incidence of foot ulcer among patients with type

1 and type 2 diabetes in the period 2001-2014 [J]. Diabetes Res

Clin Pract, 2017, 130: 221-8.

[17] GONG Q, ZHANG P, WANG J, et al. Morbidity and

mortality after lifestyle intervention for people with impaired

glucose tolerance: 30-year results of the Da Qing Diabetes

Prevention Outcome Study [J]. Lancet Diabetes Endocrinol, 2019,

7(6): 452-61.

[18] HAW J S, GALAVIZ K I, STRAUS A N, et al. Long_xfffe_term Sustainability of Diabetes Prevention Approaches: A

Systematic Review and Meta-analysis of Randomized Clinical

Trials [J]. JAMA Intern Med, 2017, 177(12): 1808-17.

[19] LI B, CHEN L, HU X, et al. Association of Serum Uric

Acid With All-Cause and Cardiovascular Mortality in Diabetes [J].

Diabetes Care, 2023, 46(2): 425-33.

[20] HE Y, FENG J, ZHANG B, et al. Serum uric acid levels

and risk of cardiovascular disease in type 2 diabetes: results from

a cross-sectional study and Mendelian randomization analysis [J].

Front Endocrinol (Lausanne), 2023, 14: 1251451.

[21] YANG T, LIU Y, LI L, et al. Correlation between the

triglyceride-to-high-density lipoprotein cholesterol ratio and

other unconventional lipid parameters with the risk of prediabetes

and Type 2 diabetes in patients with coronary heart disease: a

RCSCD-TCM study in China [J]. Cardiovasc Diabetol, 2022,

21(1): 93.

[22] MALMSTEDT J, KÄRVESTEDT L, SWEDENBORG J,

et al. The receptor for advanced glycation end products and risk of

peripheral arterial disease, amputation or death in type 2 diabetes:

a population-based cohort study [J]. Cardiovasc Diabetol, 2015,

14: 93.

[23] PARK J H, SUH D H, KIM H J, et al. Role of

procalcitonin in infected diabetic foot ulcer [J]. Diabetes Res Clin

Pract, 2017, 128: 51-7.

[24] OZER BALIN S, SAGMAK TARTAR A, UĞUR K, et

al. Pentraxin-3: A new parameter in predicting the severity of

diabetic foot infection? [J]. Int Wound J, 2019, 16(3): 659-64.

[25] METINEREN H, DÜLGEROĞLU T C. Comparison of

the Neutrophil/Lymphocyte Ratio and C-Reactive Protein Levels

in Patients With Amputation for Diabetic Foot Ulcers [J]. Int J Low

Extrem Wounds, 2017, 16(1): 23-8.

[26] ZUBAIR M, AHMAD J. Role of growth factors and

cytokines in diabetic foot ulcer healing: A detailed review [J]. Rev

Endocr Metab Disord, 2019, 20(2): 207-17.

[27] RUPAIMOOLE R, SLACK F J. MicroRNA therapeutics:

towards a new era for the management of cancer and other diseases

[J]. Nat Rev Drug Discov, 2017, 16(3): 203-22.

[28] MOHAMMEDI K, WOODWARD M, MARRE M, et al.

Comparative effects of microvascular and macrovascular disease

on the risk of major outcomes in patients with type 2 diabetes [J].

Cardiovasc Diabetol, 2017, 16(1): 95.

[29] FIORDALISO F, CLERICI G, MAGGIONI S, et al.

Prospective study on microangiopathy in type 2 diabetic foot ulcer

[J]. Diabetologia, 2016, 59(7): 1542-8.

[30] MOHAMMEDI K, WOODWARD M, HIRAKAWA Y, et

al. Microvascular and Macrovascular Disease and Risk for Major

Peripheral Arterial Disease in Patients With Type 2 Diabetes [J].

Diabetes Care, 2016, 39(10): 1796-803.

[31] LÜDERS F, BUNZEMEIER H, ENGELBERTZ C, et

al. CKD and Acute and Long-Term Outcome of Patients with

Peripheral Artery Disease and Critical Limb Ischemia [J]. Clin J

Am Soc Nephrol, 2016, 11(2): 216-22.

[32] SANDHOLM N, GROOP P H. Genetic basis of diabetic

kidney disease and other diabetic complications [J]. Curr Opin

Genet Dev, 2018, 50: 17-24.

[33] SIMÓ R, HERNÁNDEZ C. Neurodegeneration in the

diabetic eye: new insights and therapeutic perspectives [J]. Trends

Endocrinol Metab, 2014, 25(1): 23-33.

[34] SINGHANIA N, BANSAL S, MOHANDAS S, et al. Role

of renin-angiotensin-aldosterone system inhibitors in heart failure

and chronic kidney disease [J]. Drugs Context, 2020, 9.

[35] LIU G, LI Y, PAN A, et al. Adherence to a Healthy

Lifestyle in Association With Microvascular Complications Among

Adults With Type 2 Diabetes [J]. JAMA Netw Open, 2023, 6(1):

e2252239.

[36] GENG T, ZHU K, LU Q, et al. Healthy lifestyle

behaviors, mediating biomarkers, and risk of microvascular

complications among individuals with type 2 diabetes: A cohort

study [J]. PLoS Med, 2023, 20(1): e1004135.

[37] ZHAO S, LI Y, SU C. Assessment of common risk

factors of diabetes and chronic kidney disease: a Mendelian

randomization study [J]. Front Endocrinol (Lausanne), 2023, 14:

1265719.

[38] PERRY J R, WEEDON M N, LANGENBERG C, et al.

Genetic evidence that raised sex hormone binding globulin (SHBG)

levels reduce the risk of type 2 diabetes [J]. Hum Mol Genet, 2010,

19(3): 535-44.

[39] WONG T Y, CHEUNG C M, LARSEN M, et al. Diabetic

retinopathy [J]. Nat Rev Dis Primers, 2016, 2: 16012.

[40] SONG K H, JEONG J S, KIM M K, et al. Discordance

in risk factors for the progression of diabetic retinopathy and

diabetic nephropathy in patients with type 2 diabetes mellitus [J].

J Diabetes Investig, 2019, 10(3): 745-52.

[41] JENSEN E T, RIGDON J, REZAEI K A, et al.

Prevalence, Progression, and Modifiable Risk Factors for Diabetic

Retinopathy in Youth and Young Adults With Youth-Onset Type

1 and Type 2 Diabetes: The SEARCH for Diabetes in Youth Study

[J]. Diabetes Care, 2023, 46(6): 1252-60.

[42] F E R N A N D E S S I L V A L , H O K K A N E N J ,

VANGIPURAPU J, et al. Metabolites as Risk Factors for Diabetic

Retinopathy in Patients With Type 2 Diabetes: A 12-Year Followup Study [J]. J Clin Endocrinol Metab, 2023, 109(1): 100-6.

[43] YIN L, ZHANG D, REN Q, et al. Prevalence and risk

factors of diabetic retinopathy in diabetic patients: A community

based cross-sectional study [J]. Medicine (Baltimore), 2020, 99(9):

e19236.

[44] LIU L, YUE S, WU J, et al. Prevalence and risk factors

of retinopathy in patients with or without metabolic syndrome: a

population-based study in Shenyang [J]. BMJ Open, 2015, 5(12):

e008855.

[45] GONG D, FANG L, CAI Y, et al. Development and

evaluation of a risk prediction model for diabetes mellitus type

2 patients with vision-threatening diabetic retinopathy [J]. Front

Endocrinol (Lausanne), 2023, 14: 1244601.

[46] MOONS K G, ALTMAN D G, VERGOUWE Y, et al.

Prognosis and prognostic research: application and impact of

prognostic models in clinical practice [J]. Bmj, 2009, 338: b606.

[47] MOONS K G, KENGNE A P, WOODWARD M, et al.

Risk prediction models: I. Development, internal validation, and

assessing the incremental value of a new (bio)marker [J]. Heart,

2012, 98(9): 683-90.